AlzChem Group AG (LON:0ACT)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 1.48B +60.6% |
| Revenue (ttm) | 507.40M +4.0% |
| Net Income | 58.35M +18.3% |
| EPS | 5.77 +18.9% |
| Shares Out | n/a |
| PE Ratio | 25.34 |
| Forward PE | 23.67 |
| Dividend | 1.81 (1.10%) |
| Ex-Dividend Date | May 6, 2026 |
| Volume | 12,284 |
| Average Volume | 12,541 |
| Open | 165.70 |
| Previous Close | 165.26 |
| Day's Range | 164.50 - 166.30 |
| 52-Week Range | 114.79 - 189.90 |
| Beta | 0.63 |
| RSI | 44.64 |
| Earnings Date | Apr 30, 2026 |
About AlzChem Group AG
AlzChem Group AG, together with its subsidiaries, develops, produces, and markets a range of chemical specialties in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals segment sells specialty chemical products that are used in the chemical, food, animal feed, defence technology, and renewable energies industries. This segment manufactures composite materials and adhesives, as well as silico... [Read more]
Financial Performance
In 2025, AlzChem Group AG's revenue was 575.05 million, an increase of 2.06% compared to the previous year's 563.44 million. Earnings were 63.46 million, an increase of 17.35%.
Financial numbers in EUR Financial StatementsNews
AlzChem price target raised to EUR 200 from EUR 195 at Jefferies
Jefferies raised the firm’s price target on AlzChem (ALZCF) to EUR 200 from EUR 195 and keeps a Buy rating on the shares. The firm views the company’s earnings report
AlzChem Group AG Earnings Call Transcript: Q1 2026
Revenue and profitability grew strongly in Q1 2026, led by specialty ingredients and robust demand in nutrition and defense. Major CapEx projects are on track, and full-year guidance is confirmed despite some cost pressures, with positive cash flow and a strong equity position.
AlzChem price target raised to EUR 197 from EUR 185 at Berenberg
Berenberg analyst Gerhard Orgonas raised the firm’s price target on AlzChem (ALZCF) to EUR 197 from EUR 185 and keeps a Buy rating on the shares.
AlzChem price target raised to EUR 195 from EUR 190 at Jefferies
Jefferies raised the firm’s price target on AlzChem (ALZCF) to EUR 195 from EUR 190 and keeps a Buy rating on the shares. The company’s Q4 report confirmed its continued
AlzChem Group AG Earnings Call Transcript: H2 2025
Sales and EBITDA grew year-over-year, driven by specialty chemicals and strong creatine demand, with record margins and robust cash flow. Major investments in creatine and defense capacity set the stage for double-digit growth from 2027.
AlzChem initiated with a Buy at Jefferies
Jefferies initiated coverage of AlzChem (ALZCF) with a Buy rating and EUR 190 price target The firm is positive on the company’s unique production platform and leading niche, which positions